Cargando…

Epidemiology, Clinical Presentation and Treatment of Non-Hepatic Hyperammonemia in ICU COVID-19 Patients

(1) Background: Although COVID-19 is largely a respiratory disease, it is actually a systemic disease that has a wide range of effects that are not yet fully known. The aim of this study was to determine the incidence, predictors and outcome of non-hepatic hyperammonemia (NHH) in COVID-19 in intensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tetaj, Nardi, Stazi, Giulia Valeria, Marini, Maria Cristina, Garotto, Gabriele, Busso, Donatella, Scarcia, Silvana, Caravella, Ilaria, Macchione, Manuela, De Angelis, Giada, Di Lorenzo, Rachele, Carucci, Alessandro, Capone, Alessandro, Antinori, Andrea, Palmieri, Fabrizio, D’Offizi, Gianpiero, Taglietti, Fabrizio, Ianniello, Stefania, Campioni, Paolo, Vaia, Francesco, Nicastri, Emanuele, Girardi, Enrico, Marchioni, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104133/
https://www.ncbi.nlm.nih.gov/pubmed/35566715
http://dx.doi.org/10.3390/jcm11092592
Descripción
Sumario:(1) Background: Although COVID-19 is largely a respiratory disease, it is actually a systemic disease that has a wide range of effects that are not yet fully known. The aim of this study was to determine the incidence, predictors and outcome of non-hepatic hyperammonemia (NHH) in COVID-19 in intensive care unit (ICU); (2) Methods: This is a 3-month prospective observational study in a third-level COVID-19 hospital. The authors collected demographic, clinical, severity score and outcome data. Logistic regression analyses were performed to identify predictors of NHH; (3) Results: 156 COVID-19 patients were admitted to the ICU. The incidence of NHH was 12.2% (19 patients). The univariate analysis showed that invasive mechanical ventilation had a 6.6-fold higher risk (OR 6.66, 95% CI 0.86–51.6, p = 0.039) for NHH, while in the multiple regression analysis, there was a 7-fold higher risk for NHH—but it was not statistically significant (OR 7.1, 95% CI 0.90–56.4, p = 0.062). Demographics, clinical characteristics and mortality in the ICU at 28 days did not show a significant association with NHH. (4) Conclusions: The incidence of NHH in ICU COVID-19 patients was not low. NHH did not appear to significantly increase mortality, and all patients with non-hepatic hyperammonemia were successfully treated without further complications. However, the pathogenesis of NHH in ICU patients with COVID-19 remains a topic to be explored with further research.